This is for their tier 2 formulary. All that are not tier 1 are tier 2. If you pull up tier3 formulary, afrezza is still tier3. Looks like there is a change though. On tier 2 formulary first row, the step therapy has been removed. (ST)
Mnkd cannot end the deal. Its in the contract. Only SNY can terminate. Unless SNY is found in breach of contract. I've read the contract numerous times.
Mannkind cant terminate only sny can, unless mannkind proves breach of contract
that would explain Hakan's resigning but sticking around. But why wait, why all the secrecy. So does Sanofi work through Mannkind for secretive competitive advantage. Do they keep everything quiet so as to confuse the competition with the idea that Mannkind is going belly up? they going to explode one day with 8 or so TS apps and a buyout announcement? Any benefit waiting for fiscal 2016?
Didn't Al mention they(SNY) have the rights to their processes (MNKD). and Matt said that hasn't been disclosed yet. Not sure what that meant but also saw Sanofi file for their own inhaler patent a little while back.
Thanks for comment. In CC they explained that they are doing that too. (Acquisitions) many just completed. Share buyback is only small part of capital allocation and is used to demonstrate that management thinks the shares are undervalued.
What has been deemed a disappointment and as weak is the exact opposite in my opinion. for 2016 guidance is 209-211 billion 2.15 to 2.17 EPS vs previous expectation of 211B and 2.18. Piper Jaffery, who maintains overweight outperform, modeled for 2.16 EPS and has a price target of 38. Company is guiding double digit growth on a constant currency basis and is in the midst of an exciting, impressive transformation while maintainin that growth and growing market share. Previous supply issue concerns were the result in double demand of their new machines not supply issues. More businesses are ordering more machines. Furthermore, because of the ramp up of Petrol market, convenience stores and at the pump, growth is projected for YEARS to come. Still have 100m$ to buy back shares.
Finally, Follow the cash. Using the Buffet metric, which is, LFCF/Shares Outstanding =x then Price divided by X = Y. if Y is 15 undervalued, When Y is 30 fairly valued. Based on guidance of 23% greater LFCF of 175Million. Right here at 26pps Y is 16.04 undervalued. X = 1.62 in this equation. (subtracting the repurchased shares from the current shares outstanding.) So at 38 (P. Jaffary target) Y still only =23.45 with room to run.
Headwinds are Oil based economy countries like Brazil and Russia and Forex currency headwinds. "Ceo says we continue to take share......but translation to dollar is a nightmare." Many think that the dollar could sell off soon, based on fed raising rates but speaking dovish= a sell the news event. Could be the final piece to propel this back in to the bullish trend.
In Q N A. Suntrust analyst Andrew Jeffery said matching the confidence of the ceo with conviction in investors then at this valuation Verifone is a bargain.
or the people/banks who the shares were borrowed from sold them instantly on return as to not bump stock price. Or, the large short holders have been steadily buying over time to make the cover that much easier thus not having affect on stock price. Or, large shortholders are exchanging short coverings, i.e. ledger line moves that keep from affecting stock price. 6.4 million shares traded average. 10 million over time is not really that much. squeeze will only happen if there is an event.
Judging by your responses. You seem like an investor who lost all their lunch money. Now nothing but bitter